Porcupine (PORCN) is a membrane bound O-acyltransferase that is required for Wnt palmitoylation, secretion, and biologic activity. All evaluable human Wnts require PORCN for their activity, suggesting that inhibition of PORCN could be an effective treatment for cancers dependent on excess Wnt activity. In this study, we evaluated the PORCN inhibitor Wnt-C59 (C59), to determine its activity and toxicity in cultured cells and mice. C59 inhibits PORCN activity in vitro at nanomolar concentrations, as assessed by inhibition of Wnt palmitoylation, Wnt interaction with the carrier protein Wntless/WLS, Wnt secretion, and Wnt activation of b-catenin reporter activity. In mice, C59 displayed good bioavailability, as once daily oral administration was sufficient to maintain blood concentrations well above the IC 50 . C59 blocked progression of mammary tumors in MMTV-WNT1 transgenic mice while downregulating Wnt/b-catenin target genes. Surprisingly, mice exhibit no apparent toxicity, such that at a therapeutically effective dose there were no pathologic changes in the gut or other tissues. These results offer preclinical proof-of-concept that inhibiting mammalian Wnts can be achieved by targeting PORCN with small-molecule inhibitors such as C59, and that this is a safe and feasible strategy in vivo. Cancer Res; 73(2); 1-6. Ó2012 AACR.
Introduction
Dysregulation of the Wnt signaling cascade has been implicated in multiple disorders including cancer, vascular proliferation, and tissue fibrosis. Wnt autocrine loops and paracrine Wnt secretion from stroma have been shown in multiple settings, even in diseases such as colon cancer that have mutations in downstream components of the Wnt/ b-catenin pathway (1, 2) . Wnts are upregulated in colorectal cancer cells with mutant APC, in breast cancer cell lines, and in multiple sarcomas (2, 3) . The Wnt pathway is activated in several cancers by inactivating mutations in the ubiquitin ligases RNF43 and ZNRF3 that normally downregulate the Wnt receptor Frizzled, and in colorectal cancers by R-spondin gene fusions (4) (5) (6) (7) . In addition, negative regulators of the Wnt pathway, such as sFRP1 and Dkk1, are epigenetically silenced in multiple cancers. Wnts secreted from cancer cells (8) , stromal myofibroblasts (9) , and immune cells (10) have been implicated in the process of tumorigenesis and metastasis. If these pathways are important in cancer proliferation and spread, then inhibitors of Wnts may have value as anticancer agents. Specific targeted therapies against Wnts and their receptors, including recombinant Wnt antagonists such as decoy receptors and monoclonal antibodies against individual Wnts, have shown activity in selected settings (8, 11, 12) . However, such approaches presuppose a knowledge of which Wnts are important in any given tumor.
An alternative approach to inhibit Wnt autocrine and paracrine signaling is to block the production of all active Wnts. This can be achieved by targeting a key enzyme in Wnt biosynthesis, the membrane bound O-acyltransferase PORCN. PORCN makes a good target because it is essential for the Opalmitoylation of all human Wnts (13) (14) (15) (16) . PORCN resides in the endoplasmic reticulum, where it adds palmitate to a serine (S209 in human WNT3A) that is completely conserved in all vertebrate Wnts (16) . Acylation of S209 is required for the next step in Wnt secretion, binding to the carrier protein WLS (17) . Palmitoylation is also essential for WNT to interact with Frizzled receptors outside the cell (13, 18) . While genetic ablation of PORCN slows the growth of some tumor lines in vitro, PORCN has additional nonenzymatic functions that complicate tests of its role in cancer via a knockout or RNA interference approach (19) . As an enzyme, PORCN is an attractive target for small-molecule inhibitors (20) (21) (22) . Supporting this, we have recently reported that all mammalian Wnt signaling is sensitive to PORCN expression levels, and that small changes in PORCN activity can have significant effects on developmental phenotypes (14, 15) . A Novartis PORCN inhibitor, LGK974, is in early-phase clinical trials (NCT01351103) although no peer-reviewed published information is available regarding its activity or efficacy. The development of PORCN inhibitors offers the opportunity to directly test if PORCN is a useful target in Wnt-dependent cancers in vivo.
Materials and Methods
Extensive additional experimental details are in Supplemental Material.
Reagents
HT1080 and HeLa cells were acquired from the American Type Culture Collection. Cell lines were not tested for authenticity. STF3a cells were previously reported (17) . Wnt-C59 was purchased from Cellagen Technology, and is reported in U.S. patent WO/2010/101849. w-alkynyl palmitic acid (Alk-C16) was synthesized as previously reported (23, 24) .
Administration of C59 to mice
C59 was resuspended by sonication for 20 minutes in a mixture of 0.5% methylcellulose and 0.1% Tween-80 for oral administration. MMTV-WNT1 mice were obtained from Jackson Laboratories and backcrossed at least 6 generations to C57/BL6 mice.
Results

C59 is a potent inhibitor of PORCN enzymatic activity
The small-molecule 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl) acetamide was recently developed and patented by Novartis as a Wnt signaling modulator (25) . It is commercially available under the name C59 from at least 2 sources (Cellagen Technology and Biovision), and is claimed to inhibit PORCN enzyme activity at nanomolar concentrations. However, there is no peer-reviewed published information on its efficacy and molecular target. Because a potent, bioavailable, and stable PORCN inhibitor is not yet available we evaluated C59. We find that C59 indeed functions as a bona fide PORCN inhibitor using a number of cell-based assays. C59 inhibits WNT3A-mediated activation of a multimerized TCFbinding site driving luciferase (Super8xTopFlash; STF) with an IC 50 of 74 pmol/L (Fig. 1A) . As expected for a PORCN inhibitor, Wnt secretion into culture medium is completely abrogated by C59 treatment ( Lysates were prepared and Wnt was immunoprecipitated with antibody to V5. Click chemistry was conducted to attach azido-biotin to alkyne-palmitate groups. Finally, samples were separated by SDS-PAGE and probed for biotin and WNT3A-V5. This result was reproduced in HT1080 cells (Supplementary Fig. S1C ).
(23, 24), we find that C59 prevents incorporation of palmitate into WNT3A, consistent with inhibition of PORCN activity (Fig.  1D ). C59 inhibits the activity of all splice variants of murine PORCN ( Fig. 2A) . In preliminary studies, we found that very high concentrations of C59 were required to produce developmental phenotypes in Xenopus embryogenesis. Consistent with this, while Xenopus laevis PORCN was active when expressed in PORCN-null human cells, its activity was resistant to inhibition by C59 ( Fig. 2A) . Because the Xenopus protein is 77% identical to human PORCN, this provides genetic evidence that PORCN is the molecular target of C59, suggests a mechanism for C59 drug resistance to emerge, and indicates that less related MBOAT proteins would also be unaffected by C59. Showing that inhibition of PORCN is likely to prevent all Wntmediated signaling, we found that 9 of 9 b-catenin activating Wnts and 4 of 4 additional noncanonical Wnts lost activity when cells were treated with C59 ( Fig. 2B and C) . In summary, C59 is a nanomolar inhibitor of mammalian PORCN acyltransferase activity and blocks activation of all evaluated human Wnts. Thus, we anticipate that C59 administration will prevent all human and murine Wnt-dependent signaling. Wnt autocrine loops have been reported in multiple cancer cell lines, and secreted Wnt inhibitors like sFRPs and Frzb have growth inhibitory effects on cancer cell lines as well (2, 11, 26, 27) . We therefore assessed the effects of C59 on cancer cell proliferation in vitro. C59 does not significantly inhibit the proliferation of any of 46 tested cancer cell lines in vitro at concentrations that completely inhibit PORCN (Supplementary Table S1 ). Inhibition of proliferation of a few cell lines at more than 1.5 mmol/L (20,000-fold above the IC 50 ) is likely to be a cell-type-specific off-target effect. This overall lack of toxicity indicates that Wnt secretion is not essential for most cells to proliferate in 2-dimensional culture. Our results with C59 differ from studies on the inhibitory effects of secreted Wnt inhibitors on proliferation, which we speculate may be due to the reported additional activities of these inhibitors beyond the Wnt pathway (28).
C59 can be administered to mice and prevents tumor growth
To test the role of Wnt signaling in vivo, we assessed the bioavailability and in vivo half-life of C59 in mice. After either intravenous (2.5 mg/kg) or oral administration (5 mg/kg), the compound half-life in blood was approximately 1.94 hours. Notably, C59 concentration remained greater than 10-fold above the in vitro IC 50 for at least 16 hours following a single oral dose (Fig. 3A) . On the basis of the pharmacokinetic profiling, C59 was administered once daily to test its efficacy in treating established Wnt-driven tumors. In mice carrying a mouse mammary tumor virus (MMTV)-WNT1 transgene, overexpression of murine WNT1 causes a high incidence of mammary adenocarcinomas beginning at 10 weeks of age (29) . Notably, tumors arising in these mice remain Wnt dependent but have diverse molecular phenotypes and growth rates consistent with the hypothesis that WNT1 expands a vulnerable population that then undergoes second hits (30, 31) .
To test the in vivo efficacy of C59, we transplanted fragments from 2 independent primary MMTV-WNT1 tumors orthotopically into nude mice. Following development of palpable tumors, mice were treated with either vehicle or C59, 10 mg/ kg/d for 17 days. C59 administration arrested or reversed tumor growth in all treated mice (n ¼ 22; Fig. 3B ). After 17 days of treatment, the tumors were removed and further analyzed. Final tumor weights were significantly different (Fig.  3C) . To confirm that C59 was active in immunocompetent mice, we monitored a colony of female nulliparous Bl6 MMTV-WNT1 mice for tumor development. When tumors became palpable, the mice were treated with either vehicle or C59 (5 mg/kg/d). While the number of mice enrolled in this study was smaller, again even the lower dose of C59 significantly blocked tumor growth (Fig. 3D) . Final tumor weights are shown in Supplementary Fig. S2A .
Tumor growth inhibition is associated with decreased Wnt/b-catenin signaling in tumors
To determine whether the inhibition of tumor growth was accompanied by inhibition of Wnt/b-catenin signaling, we examined the expression of selected target genes in the allograft and primary tumors by quantitative reverse-transcription PCR (qRT-PCR). Axin2, Ccnd1, c-Myc, and Tcf7 transcripts were significantly reduced in tumors from mice treated with C59 ( Fig. 4A and Supplementary Fig. S2B ). Consistent with a decrease in c-Myc and CyclinD, treated tumors also had significantly decreased proliferation as indicated by Ki67 staining (Fig. 4B) .
A major function of WNT1 is inhibition of the b-catenin destruction complex, and consistent with this, vehicle-treated tumors had abundant b-catenin in cytoplasm and nucleus. In contrast, tumors from C59-treated mice had normal membrane b-catenin staining and markedly decreased cytoplasmic and nuclear b-catenin (Fig. 4C and Supplementary Fig. S3 ). Suggesting C59 is not toxic to normal tissues at this dose, mice in the treatment group had stable body weight ( Supplementary  Fig. S2C ). Moreover, no signs of toxicity were observed in the multiple tissues histologically examined at the end of the study (Supplementary Fig. S4 ). Notably, treated mice had normal intestinal morphology and nuclear b-catenin staining was maintained in the crypts (Fig. 4D and Supplementary Fig. S4 ).
Discussion
In this study, we confirm that the small-molecule C59 is a nanomolar inhibitor of the acyltransferase activity of PORCN, and show that small-molecule-mediated inhibition of PORCN is an effective means for preventing WNT1-driven tumor growth in mice. C59 inhibits palmitoylation of Wnts and is not active against Xenopus PORCN. Thus, changes in the primary sequence of PORCN confer resistance to C59, confirming genetically that PORCN is the target of C59. C59 is more than100-fold more potent than the previously reported PORCN inhibitor IWP1. We find no apparent toxicity to cells or mice at a drug concentration that effectively inhibits MMTV-WNT1-driven tumor growth. Intestinal architecture of treated mice appears normal. A similar lack of intestinal toxicity was seen when Wnt signaling was inhibited with Fzd8CRD-Fc (11) . We speculate that Wnt-addicted tumors are hypersensitive to small reductions in Wnt activity, whereas normal tissues such as intestine are more tolerant of decreases in Wnt signals and/ or have alternative pathways for self-renewal. The Wnt pathways contribute to the progression of various cancers, via both b-catenin-activating mutations and by paracrine and autocrine Wnt signaling. Increased Wnt production has also been identified in diverse nonmalignant diseases. In many cases, the implicated Wnts may be working via nonb-catenin pathways. PORCN inhibitors may therefore have efficacy even in diseases without activated b-catenin. Thus, it is a longstanding goal to identify therapeutics that can effectively target this pathway. Our recent work has confirmed that PORCN is a key node for fine control of total Wnt-dependent cell signaling, further supporting its use as a target (14, 15) . As such, specific and bioavailable inhibitors of PORCN represent attractive new molecules that may be of value in the treatment of various cancers, in addition to other Wnt-stimulated diseases. 
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